FDA says that the GLP-1 shortage is over
US$ 27.84
glp 1 ra pancreatitis Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy GLP-1 Agonists and Pancreatitis Risk
Description
In the real world, GLP-1 outcomes are often more modest
10.1007/s40265-020-01435-4 Drugs
Obesity: A role for GLP-1 in the development of obesity was suggested partly because of the apparent physiological effects of GLP-1 on appetite and food intake, and reduced GLP-1 secretion in obesity
Conclusin Los agonistas GLP-1 son tiles en situaciones mdicas especficas, pero no son para todos
